US Patent Application 20100021548 - USE OF MICROPARTICLES WITH ADSORBED ANTIGEN TO STIMULATE IMMUNE RESPONSES
InventorsAssigneeUS Classes424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)424/208.1, Immunodeficiency virus (e.g., HIV, etc.)424/228.1, Non-A, non-B hepatitis virus or hepatitis C virus424/227.1, Hepatitis B virus (e.g., hepatitis B surface antigen (HBsAg), pre-S region, hepatitis B core antigen (HBcAg), hepatitis B e-antigen, Dane particle, etc.)424/209.1Orthomyxoviridae (e.g., influenza virus, fowl plague virus, etc.)Attorney, Agent or FirmInternational ClassesA61K 9/14A61K 39/21 A61K 39/29 A61K 39/145 Claims1. A composition comprising an antigen derived from a pathogen adsorbed to a microparticle that comprises a poly(α-hydroxy acid); and a pharmaceutically acceptable excipient. 2. The composition of claim 1, wherein said antigen is derived from a viral pathogen. 3. The composition of claim 2, wherein the microparticle comprises a poly(α-hydroxy acid) selected from the group consisting of poly(L-lactide), poly(D,L-lactide) and poly(D,L-lactide-co-glycolide). 4. The composition of claim 3, wherein the microparticle comprises poly(D,L-lactide-co-glycolide). 5. The composition of claim 2, wherein the antigen comprises HIV gp120. 6. The composition of claim 2, wherein the antigen comprises HIV p24gag. 7. The composition of claim 2, wherein the antigen comprises Influenza A hemagglutinin antigen. 8. The composition of claim 2, wherein said antigen comprises a hepatitis B viral antigen. 9. The composition of claim 2, wherein said antigen comprises a hepatitis C viral antigen. 10. The composition of claim 2, wherein said antigen comprises an influenza A viral antigen. 11. The composition of claim 2, wherein said antigen comprises an HIV antigen. 12. The composition of claim 2, wherein said composition is an injectable composition. 13. The composition of claim 2, wherein said composition further comprises an immunological adjuvant. 14. The composition of claim 13, wherein the immunological adjuvant comprises a monophosphorylipid A compound. 15. The composition of claim 2, wherein the microparticle has a diameter between 500 nanometers and 10 microns. 16. The composition of claim 2, wherein the microparticle comprises a poly(lactide-co-glycolide). 17. The composition of claim 16, wherein said poly(lactide-co-glycolide) contains 50% D,L-lactide and 50% glycolide. |
| ||||||||||||||
